142 related articles for article (PubMed ID: 30362248)
21. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
[TBL] [Abstract][Full Text] [Related]
22. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Goyal G; Bhatt VR
Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
[TBL] [Abstract][Full Text] [Related]
23. Practice of bridging anticoagulation: guideline adherence and risk factors for bleeding.
Eijgenraam P; ten Cate H; ten Cate-Hoek AJ
Neth J Med; 2014 Apr; 72(3):157-64. PubMed ID: 24846933
[TBL] [Abstract][Full Text] [Related]
24. Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients.
Attaya H; Wysokinski WE; Bower T; Litin S; Daniels PR; Slusser J; Heit JA; McBane RD
J Thromb Thrombolysis; 2013 Jan; 35(1):100-6. PubMed ID: 22843195
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications.
Kelddal S; Nykjær KM; Gregersen JW; Birn H
BMC Nephrol; 2019 Apr; 20(1):139. PubMed ID: 31023275
[TBL] [Abstract][Full Text] [Related]
26. Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
Malhotra P; Jain S; Kapoor G
J Pediatr Hematol Oncol; 2018 Oct; 40(7):e450-e453. PubMed ID: 29554021
[TBL] [Abstract][Full Text] [Related]
27. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
28. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation.
Wysokinski WE; McBane RD; Daniels PR; Litin SC; Hodge DO; Dowling NF; Heit JA
Mayo Clin Proc; 2008 Jun; 83(6):639-45. PubMed ID: 18533080
[TBL] [Abstract][Full Text] [Related]
29. Thromboembolism in children with cancer: a retrospective multicenter study in Korea.
Choi HS; Kim HJ; Kang HJ; Lee JW; Shin HY; Park HJ; Park BK; Lee YH; Lee JA; Lim YJ; Park KD
J Thromb Thrombolysis; 2019 May; 47(4):558-565. PubMed ID: 30666552
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K; Minden M; Chan SM; Gupta V; Murphy T; Sakurai N; Atenafu EG; Brandwein JM; Seki JT
Br J Haematol; 2020 Dec; 191(5):748-754. PubMed ID: 32395867
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
Harlev D; Zaidman I; Sarig G; Ben Arush MW; Brenner B; Elhasid R
Thromb Res; 2010 Aug; 126(2):93-7. PubMed ID: 20546854
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis.
Pelland-Marcotte MC; Tole S; Pechlivanoglou P; Brandão LR
Thromb Haemost; 2019 Dec; 119(12):2034-2042. PubMed ID: 31600808
[TBL] [Abstract][Full Text] [Related]
33. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
[TBL] [Abstract][Full Text] [Related]
34. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
36. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
37. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
Qureshi A; Mitchell C; Richards S; Vora A; Goulden N
Br J Haematol; 2010 May; 149(3):410-3. PubMed ID: 20201945
[TBL] [Abstract][Full Text] [Related]
38. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
39. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.
Sibai H; Seki JT; Wang TQ; Sakurai N; Atenafu EG; Yee KW; Schuh AC; Gupta V; Minden MD; Schimmer AD; Brandwein JM
Curr Oncol; 2016 Aug; 23(4):e355-61. PubMed ID: 27536184
[TBL] [Abstract][Full Text] [Related]
40. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.
Deerhake JP; Merz JC; Cooper JV; Eagle KA; Fay WP
J Thromb Thrombolysis; 2007 Apr; 23(2):107-13. PubMed ID: 17221327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
